Methods and uses of slit for treating fibrosis
US-2016120940-A1 · May 5, 2016 · US
Method using slit-robo system to treat sarcopenia
US10897923B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10897923-B2 |
| Application number | US-201716308435-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2017 |
| Priority date | Jun 8, 2016 |
| Publication date | Jan 26, 2021 |
| Grant date | Jan 26, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method using a SLIT-ROBO system to treat sarcopenia and, more specifically, to a method comprising administration of a gene selected from among slit1, slit2, slit3, robo1, robo2, and fragments thereof, or a protein expressed from the gene as an effective method for treating a muscle disease or for improving muscular function.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a muscle disease caused by decrease in differentiation of myoblast into myotube, muscle wasting or muscle degeneration, the method comprising the steps of: administering one protein selected from a group consisting of amino acid sequences of the following SEQ ID Nos. 1 and 4, or a gene encoding the same to an individual in need thereof: a Slit3 protein consisting of an amino acid of SEQ ID No. 1; and a LRRD2 protein domain consisting of an amino acid of SEQ ID No. 4. 2. A method for improving muscular function in a muscle disease caused by decrease in differentiation of myoblast into myotube, muscle wasting or muscle degeneration, the method comprising the steps of: administering one protein selected from a group consisting of amino acid sequences of the following SEQ ID Nos. 1 and 4, or a gene encoding the same to an individual in need thereof: a Slit3 protein consisting of an amino acid of SEQ ID No. 1; and a LRRD2 protein domain consisting of an amino acid of SEQ ID No. 4. 3. A method for treating a muscle disease caused by Robo1 or Robo2 deficiency, the method comprising the steps of: administering a gene encoding one protein selected from a group consisting of amino acid sequences of the following SEQ ID Nos. 2 and 3 to an individual in need thereof: a Robo1 protein consisting of an amino acid of SEQ ID No. 2; and a Robo2 protein consisting of an amino acid of SEQ ID No. 3. 4. A method for improving muscular function in a muscle disease caused by Robo1 or Robo2 deficiency, the method comprising the steps of: administering a gene encoding one protein selected from a group consisting of amino acid sequences of the following SEQ ID Nos. 2 and 3 to an individual in need thereof: a Robo1 protein consisting of an amino acid of SEQ ID No. 2; and a Robo2 protein consisting of an amino acid of SEQ ID No. 3.
Assignees
Inventors
Classifications
involving cells · CPC title
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
- A61K38/1709Primary
from mammals · CPC title
Nucleosides; Nucleotides; Nucleic acids · CPC title
- A23L33/18Primary
Peptides; Protein hydrolysates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10897923B2 cover?
- The present invention relates to a method using a SLIT-ROBO system to treat sarcopenia and, more specifically, to a method comprising administration of a gene selected from among slit1, slit2, slit3, robo1, robo2, and fragments thereof, or a protein expressed from the gene as an effective method for treating a muscle disease or for improving muscular function.
- Who is the assignee on this patent?
- Dae Woong Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).